RxDoctor Payments Data

Tara Cumming, NP

Acute Care · San Antonio, TXNPI 1831632066

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (47.0%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Photocure Inc accounts for 86.0% of it on its own, with 15 other manufacturers making up the rest. Among acute care clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$12,204in general payments, 2019–2025

Across 47 payments — averaging $259.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Photocure Inc$10K
  • Teleflex LLC$976
  • Medtronic$182
  • KARL Storz Endoscopy-america$78
  • Sumitomo Pharma America, Inc.$72
  • Johnson & Johnson$59
  • plus $342 from 10 others

What the payments were for

  • Consulting fees$1,72514%
  • Speaking & faculty fees$5,73047%
  • Travel & lodging$3,43428%
  • Food & beverage$1,31511%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,204 in reported general payments places this provider in the 95th percentile of 2,323 acute care providers in Texas.

See all acute care providers in Texas

Medicare billing

Part B allowed, 2024
$40,524
Medicare patients
298
Services billed
564

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron67$69,547
GemtesaVibegron67$65,781
Mirabegron ErMirabegron12$7,149
Tamsulosin Hcl301$5,372
Finasteride307$4,284
Trospium Chloride ErTrospium Chloride16$3,707
Estradiol29$2,078
Solifenacin Succinate29$1,601
Trospium Chloride29$1,033
Tolterodine Tartrate ErTolterodine Tartrate15$1,000
NitrofurantoinNitrofurantoin Macrocrystal28$997
Oxybutynin Chloride ErOxybutynin Chloride13$789
Dutasteride32$690
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst60$660
Ciprofloxacin Hcl69$324

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$55$69,54767 claims
Sumitomo Pharma America, Inc.Gemtesa$72$65,78167 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,323 acute care providers in Texas.

Other acute care in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →